Amgen Inc. (AMGN) Given “Hold” Rating at BMO Capital Markets
BMO Capital Markets reaffirmed their hold rating on shares of Amgen Inc. (NASDAQ:AMGN) in a research note issued to investors on Friday morning. The firm currently has a $198.00 target price on the medical research company’s stock.
Other analysts have also issued research reports about the stock. Oppenheimer Holdings, Inc. reissued an outperform rating and issued a $203.00 price target (up previously from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. Royal Bank Of Canada initiated coverage on shares of Amgen in a research note on Thursday, September 14th. They set a sector perform rating and a $192.00 price objective for the company. Credit Suisse Group reaffirmed a neutral rating and set a $186.00 price objective (up previously from $177.00) on shares of Amgen in a research note on Friday, September 29th. Mizuho reaffirmed a buy rating and set a $195.00 price objective on shares of Amgen in a research note on Sunday, July 9th. Finally, Jefferies Group LLC reaffirmed a buy rating and set a $195.00 price objective on shares of Amgen in a research note on Tuesday, July 11th. Twelve research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $189.94.
Shares of Amgen (NASDAQ AMGN) traded down 0.63% on Friday, hitting $182.96. 3,179,172 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $185.13 and its 200 day moving average is $171.60. The firm has a market cap of $133.50 billion, a P/E ratio of 16.66 and a beta of 1.36. Amgen has a 12 month low of $133.64 and a 12 month high of $191.10.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. During the same quarter in the previous year, the firm posted $2.84 earnings per share. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, equities analysts predict that Amgen will post $12.58 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/21/amgen-inc-amgn-given-hold-rating-at-bmo-capital-markets.html.
In related news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $185.95, for a total transaction of $283,573.75. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.19% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. APG Asset Management N.V. boosted its holdings in shares of Amgen by 1.3% during the 3rd quarter. APG Asset Management N.V. now owns 1,614,772 shares of the medical research company’s stock valued at $301,074,000 after acquiring an additional 20,300 shares during the last quarter. Carnick & Kubik Group LLC raised its stake in Amgen by 66.4% during the 3rd quarter. Carnick & Kubik Group LLC now owns 18,166 shares of the medical research company’s stock worth $3,387,000 after acquiring an additional 7,246 shares during the period. Foster & Motley Inc. raised its stake in Amgen by 3.3% during the 3rd quarter. Foster & Motley Inc. now owns 46,520 shares of the medical research company’s stock worth $8,674,000 after acquiring an additional 1,482 shares during the period. Financial Advisory Service Inc. raised its stake in Amgen by 253.0% during the 3rd quarter. Financial Advisory Service Inc. now owns 6,969 shares of the medical research company’s stock worth $1,299,000 after acquiring an additional 4,995 shares during the period. Finally, Honkamp Krueger Financial Services Inc. raised its stake in Amgen by 10.0% during the 3rd quarter. Honkamp Krueger Financial Services Inc. now owns 5,928 shares of the medical research company’s stock worth $1,105,000 after acquiring an additional 538 shares during the period. 78.08% of the stock is currently owned by hedge funds and other institutional investors.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.